Teva has added to its vast portfolio in the US by introducing the first generic version of Viatris’ Perforomist for chronic obstructive pulmonary disease, as well as a generic of Soolantra to treat rosacea.
Teva has bolstered its respiratory portfolio in the US after launching the first generic version of Viatris’ Perforomist(formoterol fumarate) inhalation solution 20mcg/2ml vial.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Generics Bulletin reviews global regulatory developments across the world.
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
Sandoz has reached an agreement with AbbVie to dismiss without prejudice patent-infringement litigation involving more than 20 patents shielding the originator’s blockbuster JAK inhibitor Rinvoq.
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.
As the Trump Administration continues to send ripples across industries, Tevogen has launched a new generic drugs-focused endeavor that plans to reshore production to the US.
Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.
